Funding of the Clinical Trial and Payments Sample Clauses

Funding of the Clinical Trial and Payments. Za provádění klinického hodnocení za podmínek stanovených touto smlouvou uhradí PPD poskytovateli odměnu dle Přílohy 2. Poskytovateli nebude vyplacena odměna za subjekty zařazené bez řádně podepsaného informovaného souhlasu nebo takové, které nesplňují kritéria pro zařazení do klinického hodnocení. Poskytovatel sám odmění veškeré další právnické a fyzické osoby, které se budou na provádění klinického hodnocení podíle vyjma. Hlavního zkoušejícího a studijního týmu – tito budou odměněni na základě separátní smlouvy s hlavním zkoušejícím uzavřené mezi PPD a hlavním zkoušejícím. Poměr rozdělení původního rozpočtu mezi poskytovatele a zkoušejícího (včetně studijního týmu je 50:50
AutoNDA by SimpleDocs
Funding of the Clinical Trial and Payments. Za provádění klinického hodnocení za podmínek stanovených touto smlouvou uhradí PPD poskytovateli odměnu dle Přílohy 1 („rozpočet“). Poskytovateli nebude vyplacena odměna za subjekty zařazené bez řádně podepsaného informovaného souhlasu nebo takové, kteří nesplňují kritéria pro zařazení do klinického hodnocení. Odhadovaná hodnota splatná dle této smlouvy je 620 970,- Kč.
Funding of the Clinical Trial and Payments. Za provádění klinického hodnocení za podmínek stanovených touto smlouvou uhradí PPD poskytovateli a hlavnímu zkoušejícímu odměnu dle Přílohy 1 („rozpočet“). Poskytovateli ani hlavnímu zkoušejícímu nebude vyplacena odměna za subjekty zařazené bez řádně podepsaného informovaného souhlasu nebo takové, které nesplňují kritéria pro zařazení do klinického hodnocení. Platby budou vypláceny poskytovateli a hlavnímu zkoušejícímu odděleně, 5.1 As consideration for the performance under the terms and conditions of this Agreement, PPD will pay the Institution and the Principal Investigator in accordance with Schedule 1 (the “ Budget”). Institution nor Principal Investigator will not be compensated for any Subjects who were enrolled without a properly executed informed consent form or who do not meet the inclusion/exclusion criteria for the Clinical Trial. Approximate amount payable under this na jejich separátní účty, tak jak jsou uvedené v Příloze 1. Odhadovaná hodnota splatná této smlouvy je xxx Agreement is xxx CZK.
Funding of the Clinical Trial and Payments. Za provádění klinického hodnocení za podmínek stanovených touto smlouvou uhradí PPD poskytovateli odměnu dle Přílohy 1 („rozpočet“). Poskytovateli nebude vyplacena odměna za subjekty zařazené bez řádně podepsaného informovaného souhlasu nebo takové, které nesplňují kritéria pro zařazení do klinického hodnocení. Platby/odměny uvedené v tomto článku a Příloze 1 představují jediný a výlučný způsob řádného finančního vypořádání mezi všemi smluvními stranami. GSK a PPD tímto prohlašují, že neuzavřeli s hlavním zkoušejícím separátní smlouvu na odměnu za provedení klinického hodnocení. Poskytovatel sám odmění veškeré další právnické a fyzické osoby, které se budou na provádění klinického hodnocení podílet, zejména hlavního zkoušejícího a řešitelský tým. Odhadovaná hodnota splatná dle této smlouvy je 2 248 480,- Kč.
Funding of the Clinical Trial and Payments. Za provádění klinického hodnocení za podmínek stanovených touto smlouvou uhradí PPD poskytovateli odměnu dle Přílohy 2. Poskytovateli nebude vyplacena odměna za 5.1 As consideration for the performance under the terms and conditions of this Agreement, PPD will pay the Institution in accordance with Schedule 2. Institution will not be subjekty zařazené bez řádně podepsaného informovaného souhlasu nebo takové, které nesplňují kritéria pro zařazení do klinického hodnocení. compensated for any Subjects who were enrolled without a properly executed informed consent form or who do not meet the inclusion/exclusion criteria for the Clinical Trial.

Related to Funding of the Clinical Trial and Payments

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Payment Authorization and Payment Remittance a. By providing us with names and telephone numbers, email addresses, and/or bank account information of Receivers to whom you wish to direct payments, you authorize us to follow the Payment Instructions that we receive through the Service. Once registered, you authorize us to credit your Eligible Transaction Account for payments remitted to you on behalf of a Sender without further approval from you. b. When we receive a Payment Instruction from you, you authorize us to debit your Eligible Transaction Account for the amount of any such Payment Instruction plus any related fees in effect (and as disclosed on the Site) at the time you initiate the Payment Instruction, and to remit funds on your behalf. You acknowledge and agree that any applicable fees will be charged when we receive a Payment Instruction from you, regardless of whether the Payment Instruction is ultimately completed. You also authorize us to credit your Eligible Transaction Account for the receipt of payments, including but not limited to those payments returned to us from Receivers to whom you sent payment(s) and those payments that were cancelled and returned to you because the processing of the Payment Instruction could not be completed. c. You acknowledge and agree that if your Payment Instructions identify an account by name and account number, the relevant financial institution may execute those Payment Instructions by reference to the account number only, even if such account number does not correspond to the account name. You further acknowledge and agree that financial institutions holding the account may choose to not investigate discrepancies between account names and account numbers and that we have no responsibility to investigate discrepancies between account names and account numbers. d. You agree that we will not be liable in any way for any payments that you may receive, regardless of whether you authorized the Sender to send them to you. e. We will use reasonable efforts to complete all your Payment Instructions properly. However, we shall incur no liability if we are unable to complete any transaction because of the existence of any one or more of the following circumstances: 1. If, through no fault of ours, the Eligible Transaction Account does not contain sufficient funds to complete the Payment Instruction or the Payment Instruction would exceed the credit limit of your overdraft account; 2. The Service is not working properly and you know or have been advised by us about the malfunction before you execute the Payment Instruction; 3. The payment is refused as described in Section 20 below; 4. You have not provided us with the correct information, including but not limited to the correct Payment Instructions or Eligible Transaction Account information, or the correct name and address or mobile phone number of the Receiver to whom you are initiating a Payment Instruction; and/or, 5. Circumstances beyond our control (such as, but not limited to, fire, flood, network or system down time, issues with the financial institution, or interference from an outside force) prevent the proper execution of the Payment Instruction. f. It is the responsibility of the Sender and the Receiver to ensure the accuracy of any information that they enter into the Service (including but not limited to the Payment Instructions and name, telephone number and/or email address for the Receiver to whom you are attempting to send a payment), and for informing us as soon as possible if they become aware that this information is inaccurate. We will make a reasonable effort to stop or recover a payment made to the wrong person or entity once informed, but we do not guarantee such stoppage or recovery and will bear no responsibility or liability for damages resulting from incorrect information entered by the Sender or Receiver.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!